News - Tysabri, Neurological


Current filters:


Popular Filters

Elan sells its Tysabri rights to Biogen; posts 2012 financials


Ireland-based drugmaker Elan Corp (NYSE: ELN) said yesterday that partner US biotech firm Biogen Idec…

Biogen IdecBiotechnologyElanFinancialMergers & AcquisitionsNeurologicalPharmaceuticalTysabri

US multiple sclerosis market growth remains centered on Tysabri and Gilenya ahead of Aubagio's launch


The average satisfaction rating for Biogen Idec (Nasdaq: BIIB) and Elan's (NYSE: ELN) Tysabri (natalizumab).…

AubagioBiogen IdecBiotechnologyElanGilenyaMarkets & MarketingNeurologicalNorth AmericaNovartisPharmaceuticalSanofiTysabri

US neurologists' adoption of STRATIFY JCV has shifted Tysabri earlier in the treatment of some MS patients


In the USA, 77% of surveyed neurologists have experience with the STRATIFY JCV assay - commercially available…

AvonexBiogen IdecElanGilenyaMarkets & MarketingNeurologicalNorth AmericaNovartisPharmaceuticalTysabri

New analysis of risk stratification for Biogen and Elan's Tysabri


US biotech company Biogen Idec (Nasdaq: BIIB) and Ireland-based partner Elan (NYSE: ELN) said that a…

Biogen IdecBiotechnologyElanNeurologicalPharmaceuticalResearchTysabri

FDA updates Tysabri label relating to anti-JCV


The US Food and Drug Administration on Friday approved a product label change for Tysabri (natalizumab),…

Biogen IdecBiotechnologyElanNeurologicalNorth AmericaPharmaceuticalRegulationTysabri

Early treatment with Biogen and Elan’s Tysabri reduces MS relapse rates


US biotech firm Biogen Idec (Nasdaq: BIIB) and Ireland-based Elan Corp (NYSE: ELN) have released new…

Biogen IdecBiotechnologyElanImmunologicalsNeurologicalPharmaceuticalResearchTysabri

Back to top